Project Grant R01HL167986
Award Date
7/1/24
Completion Date
3/31/29
Dollars Obligated
$671K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This $3,596,019 Project Grant was awarded on May 1, 2024 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The primary objective is to evaluate the diagnostic utility of left atrial/left atrial appendage (LA/LAA) stasis measured by 4D flow MRI and other biomarkers of atrial cardiopathy in predicting recurrent ischemic stroke and new atrial fibrillation (AF) development in patients with embolic stroke of undetermined...
This $815,229 federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The objective is to use proteomics and genomics to identify biological pathways responsible for the development of cardiac dysfunction, including heart failure and atrial fibrillation, and to understand how social determinants of health impact disease risk and resilience in Black Americans.
The grant supports the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $695,882 to New York University (NYU) School of Medicine to conduct research on therapeutic modulation of atrial remodeling. The research aims to investigate the use of all-trans retinoic acid (ATRA) to prevent and reverse atrial remodeling, a key process underlying atrial fibrillation (AF). The project will utilize comparative...
This $570,537 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of California, Davis to investigate the mechanisms by which calcium homeostasis dysregulation in human atrial fibroblasts contributes to atrial fibrosis and the development of atrial fibrillation. The key objectives are to directly measure the ion channels and molecular regulators of calcium...
This federal Project Grant award of $100,050 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports comparative effectiveness research on the use of new cardiometabolic agents, including glucagon-like peptide 1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT2I), and metformin, as well as bariatric surgery, in reducing the burden of atrial fibrillation (AF). The research will utilize the...
This federal Project Grant award, with ID R01HL177651, was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $769,761 award, with a project period from January 2025 to November 2028, is funding research at Weill Medical College of Cornell University to investigate the mechanisms by which obesity leads to atrial fibrillation (AF), a common heart rhythm disorder.
The key objectives of this research project are...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $169,974 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the role of non-canonical WNT signaling in the pathogenesis of atrial fibrillation.
The overarching objective is to better define the involvement of non-canonical WNT signaling in various models of atrial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project aims to leverage high-throughput functional genomic approaches, including cell painting and Perturb-seq, to systematically assess the impact of HF-associated genetic risk loci on...
This $461,556 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to understand the role of factor XIIa (FXIIa) in modulating the progression of dilated cardiomyopathy (DCM) and heart failure with reduced ejection fraction (HFrEF).
The University of Arizona, the prime awardee, will combine enzymology, biomarker analysis, and HFrEF modeling to test the hypothesis that in DCM, FXIIa...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $599,342 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of California, Davis to identify key molecular and cellular changes in heart failure with preserved ejection fraction (HFpEF), and investigate the impact of HFpEF phenotypic heterogeneity on disease mechanisms and potential therapies. The project aims to develop refined computational models informed by novel functional and transcriptomic data,...